News & Topics

HOME > News & Topics > Topics > FY 2018 > Osaka Univ and Otsuka Pharma to Enter into an Executive Licensing Agreement on Novel "CAR-T Cell Therapy" for Multiple Myeloma

Osaka Univ and Otsuka Pharma to Enter into an Executive Licensing Agreement on Novel "CAR-T Cell Therapy" for Multiple Myeloma

Osaka University and Otsuka Pharmaceutical Co., Ltd. entered into an exclusive, worldwide license of patents associated with MMG49 CAR-T cell therapy. MMG49 CAR-T cell therapy specifically targets the active conformer of integrin β7 identified in Osaka University.

MMG49 CAR-T cell based therapy is a novel treatment of multiple myeloma, which has been developed by a research group comprising Associate Professor Naoki Hosen, (Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine), Professor Atsushi Kumanogoh (Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, IFReC).



News Release Link

"CAR-T Cell Therapy" Link

Archives

 
TOPに戻る